Pharmaceutical industry – Page 26
-
ArticleThe dark side of chemical patents
Unloved, ignored and misunderstood but could all that change?
-
FeatureUnderstanding Alzheimer’s
After hundreds of failed drug candidates, James Mitchell Crow asks if this is the last roll of the dice for the amyloid theory of Alzheimer’s disease
-
Feature3D printing in pharma
Nina Notman explores how 3D printing is carving out a niche for itself in the pharmaceutical industry
-
BusinessDeal protects world’s biggest selling drug from biosimilar erosion
AbbVie and Samsung Bioepis resolve patent litigation over arthritis drug Humira
-
BusinessIndia creates national drugs database to address supply and quality issues
Regulatory body takes steps to reform how it manages and monitors pharmaceuticals
-
BusinessNovartis’ $8.7bn AveXis deal shows gene therapy appeal
Acquisition indicates the value of potentially permanent cures for inherited diseases
-
-
ResearchSolving the crystal maze
Workflow swaps gut feelings for data when designing continuous crystallisation processes
-
BusinessFit for repurpose
Drugs that can be used for new indications offer a potentially cheaper pathway – but only if the investors can recoup their costs
-
FeatureCuba: socialism, cigars and biotech
Nina Notman learns how biotechnology could potentially overtake cigars as Cuba’s most famous export
-
NewsBrexit analysis predicts chemical industry contraction
UK government forced to publish briefing that suggests production will fall by up to 16%
-
ArticlePharma and academia: a recipe for success
More big pharmaceutical companies are collaborating with universities
-
NewsEnglish health service could recover £500m in drug costs from Pfizer
NHS England may have paid over the odds for pain drug whose patent has now been revoked
-
BusinessIndian court seizes former Ranbaxy owners’ assets
Daiichi Sankyo inches closer to recovering money from Singh brothers
-
BusinessChemist caught stealing and dumping cyanide
Merck & Co senior analytical chemist arrested for stealing and then dumping highly toxic substance down a curbside drain
-
BusinessBMS stimulates cancer drug hopes with giant collaboration
Immunooncology pioneer will pay up to $3.6bn in hope Nektar drug will help non-responders
-
NewsIllegal antibiotic combinations threaten efforts to battle antimicrobial resistance
Unapproved formulations make up two-thirds of combination therapies sold in India
-
BusinessSanofi enters M&A bonanza
French drugmaker strengthens rare diseases portfolio with blood disorder purchases
-
NewsApotex chief executive steps down amid tumult at generics firm
President and chief executive of Canada’s biggest generic drugmaker resigns the same day that police announce its founder and his wife were murdered
-
OpinionWhy modern chemists need to think big
The lessons we can learn from the larger reaction scales of the past